By Leigh Hart, Senior Moderator @ LDA Research
Rare diseases affect an estimated 300–400 million people worldwide, yet progress in diagnosis and treatment has historically been slow. Small patient populations, limited commercial incentives, and gaps in clinical knowledge have long created barriers.
In recent years, however, genuine hope has emerged. Because of rare disease networks, the story of rare diseases is no longer one of silence. It is not always clear whether advances stem from the coordinated work of networks, decades of patient advocacy, or supportive regulatory frameworks such as the Orphan Drug Act and the Paediatric Research Equity Act. What is clear is that when innovation arrives, its impact can be transformative.
Success Stories: Targeted Therapies and New Hope
One of the earliest successes was Diurnal (diroximel fumarate), developed to provide a safer, more tolerable therapy for adrenal insufficiency. For patients like Anna, who endured years of fatigue and the constant risk of adrenal crisis, a more stable treatment has been life-changing. “For the first time in years, I don’t wake up scared of what my body might do,” she explains.
Another landmark is Takhzyro (lanadelumab) for hereditary angioedema (HAE), a rare and potentially life-threatening condition characterised by sudden swelling. Before treatment, patients like James lived in fear of an airway obstruction within minutes. Now, with attacks dramatically reduced, he can travel, work, and plan for the future. “It feels like I got my freedom back,” he says.
Progress has also been recently reported in Barth syndrome, a rare genetic condition affecting mitochondria and muscle strength. Early clinical data found measurable improvements in muscle and cardiac function, and the FDA has recently granted accelerated approval for Forzinity (elamipretide), the first approved therapy for this condition. For boys like Daniel, once facing a childhood overshadowed by heart failure, the prospect of extended survival and daily strength marks a profound shift in outlook.
Even in conditions as well-known as Huntington’s disease, momentum is building. Gene-silencing therapies have aimed to reduce production of the mutant huntingtin protein. A recent trial found that the treatment slowed disease progression in 75% of patients. For families who have endured generation after generation of decline, the possibility of slowing the disease carries both scientific and emotional weight. “It may not save me, but it could change everything for my children,” reflects one parent.
In ultra-rare conditions, breakthroughs are also emerging. In a single-patient study, the compound 4-hydroxybutyrate (4-HB) has shown promise for HPDL deficiency, a disorder causing severe neurological impairment in children. For families like the Rodriguez’, whose toddler lost developmental milestones before even receiving a diagnosis, this treatment has offered something previously absent: hope. “When doctors told us there was nothing, this gave us something to hold onto,” says Mrs. Rodriguez.
Ongoing Challenges: Complexity, Access, and Unfinished Business
Yet for every success, there are conditions where progress remains painfully limited. Even as science advances, issues of complexity, access, and equity continue to hold many treatments back. Recent unsuccessful late-stage trials in several conditions underscore that safe and effective therapies for rare diseases remain a work in progress.
Duchenne muscular dystrophy (DMD) highlights the complexity of translating genetic insight into durable treatments. While exon-skipping and gene therapies have generated excitement, a recent Phase III trial failed to meet its primary endpoint, underscoring how difficult it remains to turn promise into proof. “We celebrate the progress,” one parent explains, “but it’s bittersweet when your child isn’t eligible or the trial falls short.”
Sickle cell anaemia, though more common than many rare diseases, continues to expose deep inequities in access. A late-stage setback for a gene therapy candidate reminded researchers that even scientifically sound approaches can stumble. In high-income countries, bone marrow transplants and gene therapies may be available to a few; in sub-Saharan Africa, where most children with sickle cell are born, diagnosis often comes late and supportive care is the only option. The gulf between innovation and global access remains stark.
Finally, STXBP1-related encephalopathy, a devastating early-onset epilepsy, exemplifies the limits of current understanding. Despite intense research, a recent late-stage trial for a promising compound was halted after failing to demonstrate benefit. Families continue to face relentless seizures and developmental delays with no disease-modifying therapies in sight. As Maria, a parent, describes: “Every day feels like a fight we’re not equipped for.”
Conclusion: Progress and Setbacks
Rare disease networks have demonstrated that when science, advocacy, and regulation align, extraordinary breakthroughs can follow. Treatments such as Diurnal, Takhzyro, and 4-HB show what coordinated progress can achieve, and how profoundly lives can change when the system works. Yet recent late-stage trial failures underscore how fragile and uneven progress remains, reminding us that discovery does not always translate into delivery. Sustained collaboration among researchers, regulators, industry, and patients will be essential to ensure that innovation not only advances but ultimately reaches every person still waiting for hope to become help.
